Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Pacific Biosciences of California, Inc. PACB
$12.20
+$0.05 (0.37%)
На 18:00, 12 мая 2023
-11.89%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
2994943731.00000000
-
week52high
14.20
-
week52low
3.85
-
Revenue
128304000
-
P/E TTM
-9
-
Beta
1.67058800
-
EPS
-1.45000000
-
Last Dividend
0.00000000
-
Next Earnings Date
01 авг 2023 г. в 10:59
Описание компании
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Piper Sandler | Neutral | Neutral | 18 авг 2022 г. |
| Piper Sandler | Neutral | Neutral | 16 мая 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 06 мая 2022 г. |
| Canaccord Genuity | Buy | Buy | 16 февр 2022 г. |
| Canaccord Genuity | Buy | 27 сент 2021 г. | |
| Canaccord Genuity | Buy | Buy | 16 ноя 2022 г. |
| Scotiabank | Sector Outperform | 05 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Van Oene Mark | D | 640808 | 26722 | 10 янв 2023 г. |
| HENRY CHRISTIAN O | D | 643551 | 45000 | 01 дек 2022 г. |
| Kim Susan G. | D | 163488 | 12968 | 29 сент 2022 г. |
| HENRY CHRISTIAN O | D | 688551 | 91307 | 15 сент 2022 г. |
| Van Oene Mark | A | 667528 | 300000 | 25 авг 2022 г. |
| Eidel Jeff | A | 600000 | 600000 | 16 авг 2022 г. |
| Eidel Jeff | A | 300570 | 300000 | 16 авг 2022 г. |
| MOHR MARSHALL | D | 0 | 35000 | 10 июн 2022 г. |
| MOHR MARSHALL | A | 60000 | 35000 | 10 июн 2022 г. |
| MOHR MARSHALL | A | 63015 | 63015 | 25 мая 2022 г. |
Новостная лента
PacBio (PACB) Tops on Q1 Earnings, Raises FY23 Revenue View
Zacks Investment Research
03 мая 2023 г. в 12:55
PacBio (PACB) witnesses strong revenue growth in the first quarter. This is partly aided by customers' product transition to the Revio system.
Pacific Biosciences of California (PACB) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
02 мая 2023 г. в 18:23
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.37 per share a year ago.
Assessing Pacific Biosciences And Their Revio Launch
Seeking Alpha
21 апр 2023 г. в 18:34
Assessing Pacific Biosciences And Their Revio Launch.
All You Need to Know About Pacific Biosciences (PACB) Rating Upgrade to Buy
Zacks Investment Research
11 апр 2023 г. в 13:02
Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PacBio's (PACB) New Offering to Enable High-Throughput Workflows
Zacks Investment Research
11 апр 2023 г. в 12:16
PacBio's (PACB) latest launch is expected to combine the power of HiFi sequencing and Nanobind technology to optimize sample preparation workflows for its high-volume customers.